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PCA3
ECONOMIC CONSEQUENCES OF 
MONOCLONAL ANTIBODY 17-1A ADJUVANT 
THERAPY OF RESECTED DUKES’ C 
COLORECTAL CARCINOMA IN GERMANY
Schädlich PK1, Lützelberger U2, Brecht JG1, Volmer T2
1InForMed GmbH, Hamburg, Germany; 2Glaxo Wellcome 
GmbH, Hamburg, Germany
OBJECTIVES: The purpose of our analysis was to quan-
tify the cost-effectiveness of monoclonal antibody 17-1A
(MAB) adjuvant therapy versus observation only in pa-
tients with resected Dukes’ C colorectal carcinoma (CRC),
from the perspective of a German third-party payer.
METHODS: This retrospective analysis used the cost-
effectiveness ratios “additional cost for MAB per life-year
gained (LYG)” and “per disease-free year gained (DFYG)”
as target variables and was based on a modeling approach.
Resource use in adjuvant therapy and in treatment of re-
currence was collected from a survey among specialist
health care providers. Costs were determined by multiply-
ing utilized resource items by the price or tariff of each
item. LYG and DFYG after 5 years’ follow-up were ob-
tained from the Kaplan-Meier curves of the original pa-
tient data in the clinical trial, representing a mix of 1.4/1
for colon cancer/rectal cancer. Costs and effectiveness were
discounted by 5% annually.
RESULTS: In the base-case analysis, a scenario of 30%
inpatient and 70% outpatient MAB adjuvant therapy
was applied. There were additional costs for MAB of
11,300 DM per LYG and 11,000 DM per DFYG. In the
sensitivity analysis, the impact of different treatment mo-
dalities was investigated. Exclusive inpatient administra-
tion revealed additional costs for MAB of 470 DM per
LYG and 450 DM per DFYG, whereas exclusive outpa-
tient administration revealed additional costs of 15,940
DM per LYG and 15,520 DM per DFYG. 
CONCLUSIONS: Costs of MAB adjuvant therapy in pa-
tients with CRC are counterbalanced by avoided treat-
ment costs of recurrence to great extents. The additional
cost for MAB per LYG and per DFYG vary considerably
depending on where MAB is administered.
PCA4
OUTCOME OF MONOCLONAL ANTIBODY 17-1A 
ADJUVANT THERAPY OF RESECTED COLON 
CANCER DUKES’ C IN GERMANY:
A SUBGROUP ANALYSIS
Brecht JG1, Volmer T2, Schädlich PK1, Lützelberger U2
1InForMed, GmbH, Hamburg, Germany; 2Glaxo Wellcome 
GmbH, Hamburg, Germany
OBJECTIVES: It has been argued that monoclonal anti-
body 17-1A (MAB) is more effective in colon cancer (CC)
than in colorectal cancer (CRC) Dukes’ C. The purpose
of this analysis was to estimate the cost-effectiveness of
MAB in CC versus observation only from the perspective
of a third-party payer in Germany. 
METHODS: The investigation was based on a subgroup
analysis of original data from patients with CC within the
clinical trial in patients with CRC. The modeling approach
used the cost-effectiveness ratios “additional cost for MAB
per life-year gained (LYG)” and “per disease-free year
gained (DFYG).” LYG and DFYG after 5 years were ob-
tained from the corresponding Kaplan-Meier curves. Re-
lapse prevention with MAB was nearly twice as effective in
CC as in CRC. Economic consequences of resource use,
collected from a survey, were determined by multiplying
utilized items by the prices or tariff of each item. Costs and
effectiveness were discounted by 5% per year.
RESULTS: The base-case analysis revealed additional
cost for MAB of 5,380 DM per LYG and 4,860 DM per
DFYG, when a scenario of 30% inpatient and 70% out-
patient administration was applied. In the sensitivity
analysis, there were net savings of 3,820 DM per LYG
and 3,450 per DFYG in the case of exclusive inpatient
administration and additional cost for MAB up to 9,320
DM per LYG and 8,420 DM per DFYG, when MAB was
administered on an outpatient basis exclusively. 
CONCLUSIONS: MAB is very cost-effective in patients
with CC. In inpatient administration, it results in net sav-
ings for the third-party payer while improving patients’
prognosis at the same time.
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QUALITY OF LIFE IN HODGKIN’S DISEASE: 
RESULTS FROM THE EORTC AND GHSG TRIALS
Flechtner H1, Rufer JU2
1Clinic for Child and Adolescent Psychiatry; 2Medical 
Department I, University of Cologne, Cologne, Germany
OBJECTIVES: 1) Investigating and comparing the qual-
ity of life of patients with Hodgkin’s Disease (HD) on dif-
ferent dimensions during active treatment and follow-up;
2) identifying longitudinal patterns of QoL dimensions
during re-adaptation to normal life; 3) obtaining cross-
cultural comparisons between the participating countries
and study groups (EORTC and GHSG).
BACKGROUND: Available trials addressed the negative
long-term sequelae in HD survivors, but longitudinal
data—relating the outcome to various treatment-related
variables and to the process of re-adaptation into normal
life after end of treatment—are lacking.
METHODS: Within the randomized EORTC trial H8 for
clinical stage I-II HD, which started in September 1993,
patients receive a QoL questionnaire for completion at
each follow-up visit during the first 5 years after the end
of active therapy. The corresponding HD8: Study of the
GHSG employs the assessment of QoL during and after
active treatment periods. Within both studies the EORTC
QLQ C 30 is used for quality of life assessment incorpo-
rated in the H8/HD8 questionnaire for quality of life in
HD, which addresses, in addition, the aspects of fatigue/
malaise, sexuality, specific side effects, and retrospective
evaluation of treatment.
RESULTS: To date, over 2500 questionnaires of 900 pa-
22 Abstracts
tients from both cooperative groups and 10 feasibility
problems occurred in the multicenter setting. Patients re-
ported mixed patterns of responses regarding the different
domains of QoL. Treatment-related effects could be ob-
served. In general, severe limitations in perceived QoL dur-
ing the first 3 years of follow-up were reported. In particu-
lar, levels of emotional strain and fatigue remained high
after the end of active treatment. Women in general re-
ported a lower QoL than men.
CONCLUSION: QoL assessment within international
multicenter trials in HD proved feasible within the two dif-
ferently organized study groups of EORTC and GHSG.
The applied H8/HD8 QoL questionnaire was able to de-
tect distinct patterns of QoL in subgroups of patients.
PCA6
COST-EFFECTIVENESS OF GEMCITABINE AS 
FIRST-LINE THERAPY FOR PATIENTS WITH 
ADVANCED PANCREATIC CANCER
Trippoli S, Messori A
Laboratorio SIFO di Farmacoeconomia, c/o Centro 
Informazione Farmaci, Azienda Ospedaliera Careggi,
Florence, Italy
OBJECTIVES: Gemcitabine is a new anticancer drug that
has recently been proposed for the treatment of advanced
pancreatic cancer. The therapy with gemcitabine has been
reported to confer a survival advantage in comparison
with fluorouracil. Because gemcitabine is expensive, we
estimated the cost per life-year gained using gemcitabine
for this clinical indication.
METHODS: The clinical material utilized in our analysis
was derived from a randomized clinical trial in which the
survival of patients receiving gemcitabine was compared
with that of patients receiving fluorouracil. To obtain an
estimate of effectiveness, the survival curves published in
the trial were analyzed using the Gompertz methodology.
Gemcitabine acquisition cost was based on wholesale
price in Italy, in the UK and in the US. The overall cost of
treatment is presently being estimated by collecting indi-
vidual data on the use of resources and morbidity costs.
RESULTS: The analysis of the survival curves showed
that the mean survival of patients treated with gemcitab-
ine was 6.29 months, while the corresponding value for
patients receiving standard treatment was 3.20 months
(both values include discounting at an annual rate of
3%). The survival gain for the gemcitabine group was 2.9
months per patient. Our analysis of cost data for these
two treatments is in progress, but preliminary data show
that the incremental cost is less than $20,000 per patient. 
CONCLUSIONS: In pancreatic cancer, gemcitabine de-
termines a survival gain of approximately 3 months. Its
cost-effectiveness profile seems to be within acceptable
values.
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COST ESTIMATION OF SEVERE NEUTROPENIA 
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OBJECTIVE: To collect resource utilization and unit costs
in Belgium for treatment of severe neutropenia of five
chemotreated cancer types for which no reimbursement of
prophylactic Neupogen use is available. These cancer types
include multiple myeloma (MM), metastatic breast cancer,
small cell lung cancer, non–small cell lung cancer, and blad-
der cancer. Another goal is to identify factors that may ex-
plain cost variation in treatment of severe neutropenia.
METHODS: Retrospective data collection of bills from
patients treated for severe neutropenia from nine hospital
centers spread all over Belgium over a period of 1 year
(1/96–1/97). Severe neutropenia was defined as a neutro-
penic episode requiring hospitalization. Only direct medi-
cal costs were considered from the perspective of reim-
bursement. Items collected included: hospital stay (duration
and type), diagnostic procedures, drugs, transfusions, in-
terventions; and medical consults.
RESULTS: Seventy-nine patient bills were collected. More
than 75% of the registered neutropenic events occurred dur-
ing first three chemo cycles. Total mean cost (35 Bfr  1
US$) was $4.918 (Med.: $4.529; 95% CI: $4.303–$5.533).
DISCUSSION: Multiple regression analysis demonstrates
that two factors (hospital duration and institution type)
explain 85% of the cost variation. The institution factor
may, however, mask a bias, as all the hematological can-
cers (17%) with their more costly treatment procedures
for neutropenia were treated in university centers. 85%
of treatment cost is composed of only three factors: hos-
pital stay (60%); drug regimen (15%); and lab tests per-
formed (10%). 
CONCLUSION: The treatment cost of neutropenia var-
ies. Its spread is skewed to the right. It is appropriate to
calculate geometric mean cost and to introduce specific
cost estimates per institution type or per cancer type (he-
matological/nonhematological).
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COST-MINIMIZATION IN THE USE OF COLONY-
STIMULATING FACTORS (CSFs) BASED ON 
CLINICAL PREDICTION MODELS (CPMs)
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Febrile neutropenia (FN) represents one of the leading
dose-limiting toxicities of cancer chemotherapy. CSFs have
been shown to reduce the incidence of FN in a variety of
settings. Cost-minimization models have established FN
